G Di Perri
Overview
Explore the profile of G Di Perri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
174
Citations
1089
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cosmi B, Giannella M, Fornaro G, Cristini F, Patacca A, Castagna A, et al.
BMC Infect Dis
. 2023 Oct;
23(1):718.
PMID: 37875792
Background: Randomized clinical trials in non-critically ill COVID-19 patients showed that therapeutic-dose heparin increased survival with reduced organ support as compared with usual-care thromboprophylaxis, albeit with increased bleeding risk. The...
2.
Di Girolamo L, Ferrara M, Trevisan G, Longo B, Allice T, Burdino E, et al.
Virol J
. 2023 Jun;
20(1):123.
PMID: 37312093
Background: Elite controllers are able to control viral replication without antiretroviral therapy. Exceptional elite controllers do not show disease progression for more than 25 years. Different mechanisms have been proposed...
3.
Barale M, Massano M, Bioletto F, Maiorino F, Pusterla A, Mazzetti R, et al.
Nutr Metab Cardiovasc Dis
. 2022 Jun;
32(8):1936-1943.
PMID: 35680489
Background And Aims: HIV-associated lipodystrophy syndrome (HALS) contributes to the increased cardiovascular risk connoting people living with HIV (PLHIV). HALS recognition, based on clinical ground, may be inaccurate urging an...
4.
Barco A, Orlando S, Stroffolini G, Pirriatore V, Lazzaro A, Vai D, et al.
J Neurovirol
. 2022 Jan;
28(2):226-235.
PMID: 35044644
HIV-associated neurocognitive disorders (HAND) are highly prevalent in people living with HIV (PLWH) despite successful treatment with combination antiretroviral therapy (cART). HAND pathogenesis is complex and definitive surrogate biomarkers are...
5.
Calcagno A, Cusato J, Ferrara M, De Nicolo A, Lazzaro A, Manca A, et al.
J Antimicrob Chemother
. 2020 Mar;
75(7):1969-1971.
PMID: 32211890
Objectives: An unexpected drug-drug interaction has been recently reported between dolutegravir, an HIV integrase inhibitor, and valproic acid. Despite there being several potential underlying mechanisms, plasma protein displacement has been...
6.
Montrucchio C, De Nicolo A, DEttorre G, DAscenzo F, Lazzaro A, Tettoni M, et al.
Int J Antimicrob Agents
. 2020 Jan;
55(4):105908.
PMID: 31991223
Background: The incidence of cardiovascular disorders in people living with HIV (PLWH) is higher than that in non-infected individuals. Traditional and specific risk factors have been described but the role...
7.
8.
Shafran S, Di Perri G, Esser S, Lelievre J, Parczewski M
HIV Med
. 2019 May;
20 Suppl 7:1-16.
PMID: 31099116
Since the introduction of suppressive antiretroviral therapy (ART), HIV has become a chronic disease, with infected people in high-income countries approaching similar life expectancy to the general population. As this...
9.
Guaraldi G, Marcotullio S, Maserati R, Gargiulo M, Milic J, Franconi I, et al.
J Frailty Aging
. 2019 Feb;
8(1):10-16.
PMID: 30734825
Objective: This article deals with the attempt to join HIV and geriatric care management in the 2017 edition of the Italian guidelines for the use of antiretrovirals and the diagnostic-clinical...
10.
Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, DAvolio A, et al.
J Antimicrob Chemother
. 2018 Dec;
74(4):1035-1043.
PMID: 30561642
Background: Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2),...